ZA202305122B - Prophylaxis and treatment of angioedema - Google Patents
Prophylaxis and treatment of angioedemaInfo
- Publication number
- ZA202305122B ZA202305122B ZA2023/05122A ZA202305122A ZA202305122B ZA 202305122 B ZA202305122 B ZA 202305122B ZA 2023/05122 A ZA2023/05122 A ZA 2023/05122A ZA 202305122 A ZA202305122 A ZA 202305122A ZA 202305122 B ZA202305122 B ZA 202305122B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- angioedema
- human patient
- alleviate
- symptoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207273 | 2020-11-12 | ||
| PCT/EP2021/081493 WO2022101395A1 (en) | 2020-11-12 | 2021-11-12 | Prophylaxis and treatment of angioedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202305122B true ZA202305122B (en) | 2024-08-28 |
Family
ID=73401436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/05122A ZA202305122B (en) | 2020-11-12 | 2023-05-09 | Prophylaxis and treatment of angioedema |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230338358A1 (https=) |
| EP (1) | EP4243824B1 (https=) |
| JP (1) | JP2023549849A (https=) |
| KR (1) | KR20230107269A (https=) |
| CN (1) | CN116685353A (https=) |
| AU (1) | AU2021376885A1 (https=) |
| CA (1) | CA3198246A1 (https=) |
| ES (1) | ES3061585T3 (https=) |
| IL (1) | IL302887A (https=) |
| MX (1) | MX2023005563A (https=) |
| WO (1) | WO2022101395A1 (https=) |
| ZA (1) | ZA202305122B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3062067T3 (en) * | 2022-03-25 | 2026-04-08 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
| TW202345810A (zh) * | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽b2受體拮抗劑之固態延長釋放組成物 |
| WO2025037920A1 (ko) | 2023-08-16 | 2025-02-20 | 주식회사 엘지화학 | 수지 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005053660A2 (en) * | 2003-12-03 | 2005-06-16 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising danazol |
| US7816383B1 (en) * | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| AR113839A1 (es) * | 2017-11-24 | 2020-06-17 | Pharvaris B V | Antagonistas del receptor b2 de bradiquinina |
-
2021
- 2021-11-12 CN CN202180080857.7A patent/CN116685353A/zh active Pending
- 2021-11-12 IL IL302887A patent/IL302887A/en unknown
- 2021-11-12 MX MX2023005563A patent/MX2023005563A/es unknown
- 2021-11-12 KR KR1020237018410A patent/KR20230107269A/ko active Pending
- 2021-11-12 JP JP2023528620A patent/JP2023549849A/ja active Pending
- 2021-11-12 ES ES21805547T patent/ES3061585T3/es active Active
- 2021-11-12 AU AU2021376885A patent/AU2021376885A1/en active Pending
- 2021-11-12 WO PCT/EP2021/081493 patent/WO2022101395A1/en not_active Ceased
- 2021-11-12 EP EP21805547.3A patent/EP4243824B1/en active Active
- 2021-11-12 CA CA3198246A patent/CA3198246A1/en active Pending
- 2021-11-12 US US18/036,719 patent/US20230338358A1/en active Pending
-
2023
- 2023-05-09 ZA ZA2023/05122A patent/ZA202305122B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4243824B1 (en) | 2025-12-24 |
| MX2023005563A (es) | 2023-09-11 |
| ES3061585T3 (en) | 2026-04-06 |
| WO2022101395A1 (en) | 2022-05-19 |
| CN116685353A (zh) | 2023-09-01 |
| CA3198246A1 (en) | 2022-05-19 |
| IL302887A (en) | 2023-07-01 |
| KR20230107269A (ko) | 2023-07-14 |
| EP4243824A1 (en) | 2023-09-20 |
| AU2021376885A1 (en) | 2023-06-08 |
| US20230338358A1 (en) | 2023-10-26 |
| JP2023549849A (ja) | 2023-11-29 |
| EP4243824C0 (en) | 2025-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202305122B (en) | Prophylaxis and treatment of angioedema | |
| NZ572049A (en) | Method for treatment of constipation-predominant irritable bowel syndrome | |
| ZA202310050B (en) | Pharmaceutical composition for preventing or treating fibrosis | |
| WO2020186132A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| MX2023008726A (es) | Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual. | |
| MX2022011490A (es) | Tratamiento o metodo de prevencion de falla cardiaca cronica. | |
| EP4647125A3 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
| WO2021007314A3 (en) | Treatment of cancer | |
| MX2024011142A (es) | Tratamiento de neurofibromas cutaneos con mirdametinib. | |
| MX2022015760A (es) | Inhibidor del receptor tipo toll 7 (tlr7) en combinacion con prednisolona o hidroxicloroquina para el tratamiento del lupus eritematoso cutaneo. | |
| MX2022012135A (es) | Métodos para tratar la enfermedad de coronavirus de 2019. | |
| MX2025000673A (es) | Metodos de administracion de nalbufina | |
| CA3156680A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME | |
| MX2022015146A (es) | Tratamiento de la artritis reumatoide. | |
| MY200960A (en) | Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| MX2008016520A (es) | Medicamentos. | |
| MX2025007194A (es) | Antagonistas del receptor 1 del acido lisofosfatidico (lpa1) para el tratamiento de la enfermedad pulmonar intersticial | |
| WO2020025657A9 (en) | Composition for use in the prevention and/or treatment of the genitourinary mucosa | |
| ZA202407245B (en) | Novel use of pitolisant for treating severe fatigue | |
| MY203365A (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| PH12021550134A1 (en) | Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham | |
| WO2022261344A8 (en) | Subcutaneous formulation and methods for treating edema refractory to oral diuretics | |
| WO2022251752A3 (en) | Dual treatment of migraine |